Becton Dickinson Gets FDA OK for Molecular Staph Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received US Food and Drug Administration clearance to market its new assay for detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs.

The BD Max StaphSR Assay is for use on the BD Max System, a fully automated molecular diagnostic platform, and can detect mecA dropout mutants and other new strains of MRSA that may not be detected by other assays, said BD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.